Schott Pharma and Nemera Launched New Syringe System
The new 5.5 ml prefillable glass syringe system is designed to support the self-administration of large-volume biologics.
Updated on Oct. 1, 2026 in Diabetes
Live Poll
Do you believe self-administration technology for large-volume therapies makes at-home healthcare better?
SCHOTT Pharma and Nemera have launched a passive safety system designed for 5.5 ml prefillable glass syringes. This new platform aims to facilitate the subcutaneous self-administration of large-volume therapies by ensuring compatibility and usability.
Why it matters
The system addresses the growing demand for self-administered biologic treatments by reducing development complexity for pharmaceutical companies. It helps bridge the gap between complex drug requirements and the need for user-friendly home delivery systems.
The system features ultra-low tungsten residuals within the 5.5 ml glass syringe, confirmed through technical verification for injection performance. The platform has been validated through human factors studies to ensure usability for patients with varying dexterity levels.
The players
SCHOTT Pharma
This company specializes in drug containment and delivery solutions for the pharmaceutical and biotech industries.
Nemera
This organization designs and manufactures drug delivery devices, including auto-injectors and pens for the healthcare sector.
The details
The collaboration integrates a specialized safety device developed by Nemera with a high-performance glass syringe from SCHOTT Pharma. By pre-aligning the compatibility of these components, the companies have created a system now available for pharmaceutical development programs.
Timeline
October 6-7, 2026: The system will be displayed at PDA Palm Springs.
October 6-8, 2026: The system will be displayed at CPHI Milan.
Health Landscape
This development follows the broader industry trend of transitioning complex biologic treatments from clinical settings to patient-led home administration. It marks a significant milestone in simplifying the delivery of large-volume therapies that previously required professional oversight.
Patients requiring large-volume biologics may eventually gain access to more user-friendly, home-based injection options that accommodate varying physical dexterity. This could streamline daily health routines by removing the need for frequent clinical visits for subcutaneous treatments.
The takeaway
This partnership highlights how collaborative engineering can solve technical hurdles in the drug delivery market. Users should monitor updates from their healthcare providers regarding the availability of new, simplified injection devices for their specific therapies.
Further reading
Learn more about the latest innovations in home-based treatment delivery in the Diabetes section.
Source note: This article includes information reported by Manufacturingchemist.
Live Poll
Do you believe self-administration technology for large-volume therapies makes at-home healthcare better?
